Galecto enrolls first patient in GB1211 trial

Galecto announced that the first patient has been enrolled in an investigator-initiated Phase 2 trial to evaluate GB1211, Galecto’s oral small molecule galectin-3 inhibitor candidate, at the Earle A. Chiles Research Institute, or EACRI, a division of Providence Cancer Institute in Portland, Oregon. The study aims to evaluate the safety and efficacy of GB1211 at a dose of 100mg twice daily in combination with pembrolizumab for the treatment of metastatic malignant melanoma and head and neck squamous cell carcinoma.